Core Insights - Cigna reported $67.13 billion in revenue for Q2 2025, an 11% year-over-year increase, with an EPS of $7.20 compared to $6.72 a year ago, exceeding Zacks Consensus Estimates [1] - The revenue surprise was +7.09% over the consensus estimate of $62.69 billion, while the EPS surprise was +0.84% over the consensus estimate of $7.14 [1] Financial Performance Metrics - Medical Care Ratio was 83.2%, matching the average estimate by analysts [4] - Total Medical Customers reached 18.05 million, surpassing the average estimate of 17.92 million [4] - U.S. Healthcare Medical Customers were 16.36 million, slightly above the estimate of 16.23 million [4] - International Health Medical Customers were 1.69 million, in line with the estimate [4] - Net investment income was $236 million, exceeding the average estimate of $219.84 million, but representing a year-over-year decline of 26.5% [4] - Pharmacy revenues were $53.65 billion, significantly above the estimate of $49.16 billion, reflecting a 19% year-over-year increase [4] - Revenues from Evernorth Health Services were $57.83 billion, exceeding the estimate of $54.43 billion, with a year-over-year increase of 16.7% [4] - Evernorth Health Services Pharmacy revenues were $53.99 billion, surpassing the estimate of $51.33 billion, with a year-over-year increase of 16.9% [4] - Cigna Healthcare Premiums revenues were $8.99 billion, slightly above the estimate of $8.87 billion, but showing a year-over-year decline of 21.5% [4] - Total Premiums revenues were $9.16 billion, exceeding the estimate of $8.7 billion, with a year-over-year decline of 20.1% [4] - Fees and Other revenues were $4.14 billion, above the estimate of $4.05 billion, reflecting a year-over-year increase of 13.4% [4] - Cigna Healthcare revenues were $10.8 billion, slightly above the estimate of $10.78 billion, but showing a year-over-year decline of 18.2% [4] Stock Performance - Cigna's shares have returned -7% over the past month, contrasting with the Zacks S&P 500 composite's +2.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

智通财经7月31日电，德意志银行将联合健康（UNH）目标价从328美元下调至275美元。 ...

Core Insights - Humana reported $32.39 billion in revenue for the quarter ended June 2025, a year-over-year increase of 10.2% [1] - The EPS for the same period was $6.27, down from $6.96 a year ago, with a surprise of -0.79% compared to the consensus estimate of $6.32 [1] Financial Performance - The reported revenue exceeded the Zacks Consensus Estimate of $31.78 billion by 1.93% [1] - The Benefits Expense Ratio was 89.7%, slightly above the average estimate of 89.5% [4] - Medical Membership in Medicare Supplement reached 444.1 thousand, surpassing the estimate of 419.63 thousand [4] - Total Medicare Medical Membership was 8.23 million, slightly above the average estimate of 8.19 million [4] - Premium revenues were $30.72 billion, exceeding the estimate of $30.23 billion, representing a 9.2% increase year-over-year [4] - Investment income was reported at $272 million, a decrease of 8.7% year-over-year [4] - Services revenue was $1.4 billion, exceeding the estimate of $1.31 billion, reflecting a 27.3% year-over-year increase [4] - Revenue from the CenterWell segment was $5.54 billion, above the estimate of $5.21 billion, with an 11.9% year-over-year change [4] - Total Intersegment Revenues showed a change of +6.9% year-over-year, reported at -$4.34 billion compared to the estimate of -$4.18 billion [4] Stock Performance - Humana's shares have returned -7.9% over the past month, contrasting with the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]

Financial Data and Key Metrics Changes - The company raised its full year 2025 EPS outlook from approximately $16.25 to approximately $17, driven by strong performance in CenterWell Pharmacy and better than expected individual MA membership [8][21] - Medical cost trends for the second quarter were in line with expectations, with overall medical and operating costs trending in line or better than expected [21][28] Business Line Data and Key Metrics Changes - Individual MA membership declined less than expected, with a guidance adjustment now assuming a decline of around 500,000 members compared to the previous estimate of 550,000 [9][28] - CenterWell Pharmacy outperformed expectations due to higher direct-to-consumer volume and favorable specialty pharmacy dynamics [19][62] Market Data and Key Metrics Changes - The company is expanding its Medicaid footprint, now active in 10 states with three more states pending, and is optimistic about its performance in the LTSS population [18][32] - The company noted that its Medicaid performance is not directly comparable to peers due to differences in product focus and state footprints [30][32] Company Strategy and Development Direction - The company is focused on enhancing member experience through initiatives like simplifying prior authorization processes and integrating health plan information into MyChart [11][12] - A multi-year transformation is underway to create a more efficient back office, including early retirement programs and outsourcing shared services [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the core fundamentals and growth outlook for MA, believing it will deliver compelling shareholder value over the long term [20] - The company is making incremental investments of approximately $100 million to improve member outcomes and operational excellence [21][67] Other Important Information - The company is committed to maximizing shareholder value through share buybacks and prudent capital deployment strategies [22][23] - The company is monitoring the impact of recent CMS regulations and IRA changes on its Part D performance and overall strategy [36][39] Q&A Session Summary Question: Cost trends and Medicaid performance - Management indicated that overall medical and operating costs are trending in line with expectations, with Medicaid performing as anticipated [26][28][33] Question: Part D performance and CMS regulations - Part D member mix and Rx trends are tracking in line with expectations, with no unexpected behavioral changes noted [35][36] Question: Individual PPO market implications - Management believes that product and benefit structure improvements will mitigate risks associated with membership growth and margins [42][45] Question: Inpatient utilization trends in Medicare Advantage - Inpatient utilization is trending in line with expectations, with no acceleration noted [52][53] Question: Updates on STARS performance - Management is confident in operational progress and expects improvement in underlying metrics, though specific data is not available yet [56][59] Question: Specialty pharmacy strength and IRA dynamics - Specialty pharmacy outperformance is attributed to strategic partnerships and broader industry trends, with no unexpected behavioral changes in Part D noted [62][65] Question: Incremental investments and guidance - Management confirmed an additional $100 million in incremental investments aimed at driving returns and supporting transformation efforts [67][68] Question: Membership growth and operational absorption - Management is confident in the product and believes operational absorption of growth will be manageable, with a focus on long-term value [110][111]

Group 1 - US stock market futures are rising as investors prepare for the Federal Reserve's interest rate decision, economic data updates, and earnings reports from tech giants Microsoft and Meta [1][2] - The Dow Jones Industrial Average futures remain stable, while the S&P 500 futures slightly increased by 0.1% and the Nasdaq 100 futures rose by 0.2% [1] - Starbucks reported a smaller-than-expected decline in US sales, leading to a pre-market stock price increase [2] Group 2 - Boeing, Spotify, Merck, and UnitedHealth Group released their earnings reports, with only Boeing's stock price rising post-announcement [2] - The Federal Reserve is expected to maintain interest rates during its two-day policy meeting, with market attention on the "dot plot" and comments from Chairman Jerome Powell for potential signals of rate cuts later this year [2] - Microsoft and Meta are under scrutiny regarding the effectiveness of their significant investments in artificial intelligence, with their earnings reports due after market close on Wednesday [2] Group 3 - Upcoming earnings reports from Apple and Amazon are anticipated on Thursday, alongside the release of the Personal Consumption Expenditures (PCE) index, which is a favored inflation indicator by the Federal Reserve [2] - The market is also influenced by a deadline set by Trump for trade partners to reach agreements with the US, which is looming this week [2]

联合健康(UNH.US)盘初一度跌超7.6%，最低触及260.55美元，创逾两个月新低。消息面上，联合健康 Q2收入为1116亿美元，略高于市场预期的1115.9美元；调整后每股收益4.08美元，低于市场预期的4.22 美元。由于各业务线的医疗成本趋势高于预期，医疗赔付率(MLR)升至89.4%，高于市场预期的89.3%。 公司更新2025年业绩展望，预计营收为4455亿至4480亿美元，调整后每股收益为16美元，远低于此前预 期的26至26.5美元。(格隆汇) （原标题：美股异动｜联合健康一度跌超7.6%创逾两个月新低 下调全年调整后每股收益指引） ...

联合健康(UNH.N)跌超5%，公司2025财年业绩指引低于市场预期。 ...

联合健康股价下跌7.5%至5月份以来的最低水平，公司2025财年业绩指引低于预期，预计将于2026年恢 复盈利增长。 ...

来源：视频滚动新闻 联合健康第二季度调整后每股收益为4.08美元，去年同期为6.80美元，市场预期为4.59美元。预计全年 调整后每股收益至少为16美元，市场预期为20.40美元。预计将在2026年恢复盈利增长。联合健康美股 盘前大幅波动，现涨0.67%。 ...

本文源自：金融界AI电报 联合健康预计本财年调整后每股收益至少为16美元，低于市场预期的20.40美元。联合健康第二季度营 收1116.2亿美元，预估为1115.8亿美元。联合健康第二季度每股收益为3.74美元，去年同期为4.54美元。 ...